<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322449</url>
  </required_header>
  <id_info>
    <org_study_id>2016-08911</org_study_id>
    <nct_id>NCT03322449</nct_id>
  </id_info>
  <brief_title>APOA2 Gene, Diet, Inflammation and Gut Health</brief_title>
  <official_title>APOA2 Gene, Diet, Inflammation and Gut Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nutrients and chemicals in food are able to regulate expression of genetic elements.&#xD;
      Gene-nutrient interaction in response to unhealthy diets can increase an individual's risk,&#xD;
      shifting the individual from health toward the development of chronic disease. The&#xD;
      apolipoprotein A2 (APOA2) gene may either put individuals at risk for or protect from obesity&#xD;
      in the presence of certain fats in food. The main purpose of this four-week study is to&#xD;
      examine diet induced gene-nutrient interaction, with a focus on gut health, gut microbiota&#xD;
      and inflammation in individuals who have either the CC or the TT form within a specific&#xD;
      variant of the APOA2 Gene. The (2) one-week study diets, one plant based and the other animal&#xD;
      based are separated by a (1) week return to your regular habitual without probiotic or&#xD;
      prebiotic food products.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this application are 1. To use a diet intervention setting to&#xD;
      rigorously evaluate the mechanisms responsible for the previously observed effects, focusing&#xD;
      on gut microbiota and markers of gut health and inflammation and 2. To prove that targeted&#xD;
      dietary intervention based on genes can provide additional, tailored benefit to genetically&#xD;
      vulnerable individuals. The overall hypothesis proposes that significant cross-talk between&#xD;
      the human host genome, the microbiome, and the diet, defines the observed inter-individual&#xD;
      variation in metabolic and physiological responses. Accordingly, the investigators propose&#xD;
      the following specific aims and hypotheses.&#xD;
&#xD;
      AIM 1: To catalog the response of the plasma metabolome to diets differing in saturated fat&#xD;
      and prebiotics content (animal-based diet versus plant-based diet) in individuals from the&#xD;
      USA carrying CC (n=20) and TT (n=20) genotypes at the common APOA2 -265T&gt;C SNP using a&#xD;
      crossover, randomized dietary intervention study.&#xD;
&#xD;
      Our primary hypothesis states: A significant and biologically relevant proportion of the&#xD;
      individual variation in changes in the plasma metabolome in response to dietary saturated fat&#xD;
      and prebiotic intake will be due to APOA2-265T&gt;C genotypes. Specifically, subjects homozygous&#xD;
      (CC) for the less common C allele will respond to decreases in total dietary saturated fat&#xD;
      and increases in prebiotics (i.e., plant-based diet) with significantly greater improvement&#xD;
      of metabolites related to gut health, inflammation and other cardiometabolic traits than&#xD;
      subjects homozygous (TT) for the common T allele.&#xD;
&#xD;
      AIM 2: To characterize differential impacts of low SFA/high prebiotic (plant-based) diet vs.&#xD;
      high SFA/low prebiotic (animal-based) diets on gut microbiota patterns between CC and TT&#xD;
      persons at APOA2-265T&gt;C.&#xD;
&#xD;
      Our primary hypothesis states: CC subjects have a preference for high-fat and -protein foods&#xD;
      and therefore high levels of Bacteroidetes, Actinobacteria and similar species in the gut are&#xD;
      expected. Moreover, reducing intake of saturated fat and increasing prebiotics will be more&#xD;
      effective in inducing a healthier gut microflora profile in CC subjects than in those with&#xD;
      the TT genotype, with opposite effects observed when the diet is switched to one high in&#xD;
      saturated fat.&#xD;
&#xD;
      AIM 3: To integrate the metabolomic and gut microflora taxonomic information generated in&#xD;
      AIM1 and AIM2 in order to elucidate the physiological mechanism(s) by which diet impinges on&#xD;
      metabolic pathways through APOA2 genotypes.&#xD;
&#xD;
      Our primary hypothesis states: A diet low in saturated fat and high in prebiotics induces&#xD;
      beneficial changes in gut microbiota, metabolic processes and inflammation, which are&#xD;
      significantly more pronounced in CC than in TT subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized crossover dietary intervention</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tryptophan metabolism</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>The response of plasma metabolites related to tryptophan metabolism to diets differing in saturated fat and prebiotics content (animal-based diet versus plant-based diet) will vary in individuals carrying CC (n=20) and TT (n=20) genotypes at the common APOA2 -265T&gt;C single nucleotide polymorphism (SNP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satiety assessment using plasma levels of leptin</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>Plasma leptin (ng/ml) will be measured in plasma during each one of the intervention phases. The response of leptin (ng/ml) to a saturated fat rich diet will be less on subjects with the CC genotype at the APOA2 locus as compared to TT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipose tissue metabolism</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>Plasma adiponectin (micrograms/ml) will be measured in plasma during each one of the intervention phases. The response of adiponectin to a saturated fat rich diet will be less on subjects with the CC genotype at the APOA2 locus as compared to TT subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lipoproteins</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>Plasma lipoprotein concentrations in mg/dl (VLDL, LDL, HDL) and subclasses assessed by proton nuclear magnetic resonance (NMR) spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota diversity and composition</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>A low saturated fat (SFA)/high prebiotic (plant-based) diet and a high SFA/low prebiotic (animal-based) diets have a differential effect on gut microbiota patterns according to the presence of the CC or TT genotypes at the APOA2-265T&gt;C variant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of Interleukin 6 to assess inflammatory status</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>Plasma Levels of interleukin-6 (IL6) (pg/ml) will be measured during each of the dietary phases. IL6 will be higher in CC subjects at the APOA2 locus when consuming a high fat diet than when consuming a low fat diet. A low fat diet will not elicit increased IL6 levels in TT APOA2 subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of tumor necrosis factor alpha to assess regulation of immune cells</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>Plasma Levels of tumor necrosis factor alpha (TNFA)(pg/ml) measured during each diet phase, will be significantly different depending on diet and APOA2 genotype. TNFA will be higher in CC subjects at the APOA2 locus when consuming a high fat diet than when consuming a low fat diet. A low fat diet will not elicit increased TNFA levels in TT APOA2 subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of C-reactive to assess regulation of inflammation</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>Plasma Levels of C-reactive protein (CRP) (mg/L) measured during each diet phase will be significantly different depending on diet and APOA2 genotype. CRP will be higher in CC subjects at the APOA2 locus when consuming a high fat diet than when consuming a low fat diet. A low fat diet will not elicit increased CRP levels in TT APOA2 subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of Lipopolysaccharides to assess gut inflammation</measure>
    <time_frame>1 week per intervention arm</time_frame>
    <description>Plasma Levels of lipopolysaccharides (LPS) (ng/ml) will be significantly different depending on diet and APOA2 genotype. LPS will be higher in CC subjects at the APOA2 locus when consuming a high fat diet than when consuming a low fat diet. A low fat diet will not elicit increased LPS levels in TT APOA2 subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Animal Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>during this Arm, the participants will receive a diet enriched in animal products</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plant Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>during this Arm, the participants will receive a diet enriched in plant products</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Animal Diet</intervention_name>
    <description>during one week participants will receive food products enriched in animal products and with high content of fat and protein</description>
    <arm_group_label>Animal Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plant Diet</intervention_name>
    <description>during one week participants will receive plant products enriched in fiber and complex carbohydrates</description>
    <arm_group_label>Plant Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Women who are not pregnant&#xD;
&#xD;
          -  A BMI ranging between 27 and 34&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unexplained elevation in serum transaminases (i.e. &gt;1.5 times the upper limit of&#xD;
             normal) or with evidence of active liver disease, including primary biliary cirrhosis&#xD;
             or pre-existing gallbladder disease&#xD;
&#xD;
          -  Severe renal dysfunction (serum creatinine &gt;2.0mg/dL)&#xD;
&#xD;
          -  Excessive alcohol consumption (&gt;2 drinks/day)&#xD;
&#xD;
          -  Preexisting cardiovascular disease (CVD)&#xD;
&#xD;
          -  Stable exertional angina pectoris requiring sublingual nitroglycerin within the prior&#xD;
             3 months&#xD;
&#xD;
          -  Uncontrolled tyoe 2 diabetes (T2D) (fasting glucose &gt;126 mg/dl) or other significant&#xD;
             endocrine disease.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt;180 mmHg or diastolic blood&#xD;
             pressure &gt;100 mmHg).&#xD;
&#xD;
          -  History of pancreatitis within 1 yr. prior to screening.&#xD;
&#xD;
          -  Subjects on lipid lowering or diabetes medications.&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Body mass index (BMI) below 27 or greater than 34 kg/m2&#xD;
&#xD;
          -  Participants will also be excluded for drug abuse, extreme dietary habits, multiple&#xD;
             food allergies, extreme levels of physical or athletic activity, or by changes in body&#xD;
             weight &gt;20 lbs. during the last 6 months&#xD;
&#xD;
          -  Current use of antibiotics or during the previous 4 weeks.&#xD;
&#xD;
          -  Inability to follow any of the experimental diets (including being vegetarian) or to&#xD;
             perform the sampling required for this study&#xD;
&#xD;
          -  Use of herbal supplements that may alter the gut microflora&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Recent colonoscopy (within the previous two months)&#xD;
&#xD;
          -  Use of antidiarrheal medication&#xD;
&#xD;
          -  Thyroid diseases&#xD;
&#xD;
          -  Use of omega-3 supplements (unless it is discontinued one month prior to the beginning&#xD;
             of the study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Ordovas, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JM-USDA HNRCA at Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Corella D, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, Hixson JE, Straka RJ, Province M, Lai CQ, Parnell LD, Borecki I, Ordovas JM. The -256T&gt;C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clin Chem. 2007 Jun;53(6):1144-52. Epub 2007 Apr 19.</citation>
    <PMID>17446329</PMID>
  </reference>
  <reference>
    <citation>Corella D, Peloso G, Arnett DK, Demissie S, Cupples LA, Tucker K, Lai CQ, Parnell LD, Coltell O, Lee YC, Ordovas JM. APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations. Arch Intern Med. 2009 Nov 9;169(20):1897-906. doi: 10.1001/archinternmed.2009.343.</citation>
    <PMID>19901143</PMID>
  </reference>
  <reference>
    <citation>Smith CE, Tucker KL, Arnett DK, Noel SE, Corella D, Borecki IB, Feitosa MF, Aslibekyan S, Parnell LD, Lai CQ, Lee YC, Ordov√°s JM. Apolipoprotein A2 polymorphism interacts with intakes of dairy foods to influence body weight in 2 U.S. populations. J Nutr. 2013 Dec;143(12):1865-71. doi: 10.3945/jn.113.179051. Epub 2013 Oct 9.</citation>
    <PMID>24108135</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Jose Ordovas</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>APOA2</keyword>
  <keyword>Inflammation</keyword>
  <keyword>gene</keyword>
  <keyword>diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

